JBIO
Aerovate Therapeutics, Inc.21.34post−$0.01 (−0.05%)at close +$2.20 (+11.49%)
as of 19:59:45 UTCnext report Aug 14 · 9d
Earnings Room‹ back to JBIO
The report
fiscal Q2 2026 · from the company's noticeAug 14after close9days out
Expected movement
market-implied · at the Aug 4 close±21.2%is what the chain prices for this report itself, with the ordinary drift of the days around it taken out. Not a view we hold.
The full straddle prices ±21.9% over the 17 days to expiry; the rest of that is everyday movement, which the chain prices at 36% annualized.
expiry Aug 21 · first after the reportATM strike 22.5straddle 5.50ATM IV 145% vs 93% at Sep 18× 0.85 straddle-to-rangespot 21.34
Blast radius
1 linked · N-PORT + EDGARIf JBIO moves ±21.9% over this report, these carry part of it. Fund rows are arithmetic on published holding weights — what an index fund does by construction. Company rows are ranked by disclosed tie strength.
Positioning
Butterfly LadderNo options positioning captured for this ticker yet. Open interest settles once daily — check back after the next capture, or open this room again tomorrow.
The record
expected in pale · actual in full color1/7reports moved further than the options market had pricedtypically ±8.6% realized vs ±18.9% priced
May 7 '26±24.6%→+6.6%×0.27
Mar 6 '26±29.2%→+1.2%×0.04
Jan 5 '26±26.0%→−7.3%×0.28
Nov 14 '25±13.5%→+10.5%×0.78
Aug 13 '25±18.6%→−7.6%×0.41
May 14 '25±15.0%→−2.0%×0.13
May 1 '25±5.8%→+24.8%×4.29
May 13 '24+0.7%May 14 '24
pale = implied the day beforeink = the next day's close× = realized ÷ implied
2-quarter memory
Q1 FY26 · reported -0.57 · rev $0
record note
The note composes when the report lands. Nothing is written for a quarter that hasn't been read.